Shengshi Tech's DPP-4 Inhibitor 'Senglutin' Approved for Market Launch in China

Dec 04, 2024 07:30 CST Updated 07:30

CGeneTech

Small Molecule Innovative Drug Developer

NJCTTQ

Major Pharmaceutical R&D Company

Medical News

On December 3, the NMPA official website showed that the marketing application of CGeneTech's Class 1 new drug, Senaglipitin Phosphate Tablets (formerly known as: Shenggliptin), has been approved for the treatment of type 2 diabetes. Senaglipitin is a new generation highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor independently developed by CGeneTech.

On December 2, Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. announced that the Phase II clinical trial application for its first dual-target macromolecular drug in the autoimmune field—Amurefup α (CD47xCD20, IMM0306)—for the treatment of lupus nephritis (LN) has been approved by the National Medical Products Administration (NMPA).

On December 2, two generic drugs from Chia-TaiTianqing received NMPA approval for marketing in China. They are dapagliflozin metformin hydrochloride sustained-release tablets, the second approved generic of this drug in China, and palbociclib tablets, also the second approved generic of this drug in China.

Investment and Financing Pharmaceutical Affairs

On December 3, Hangzhou New Element Pharmaceutical Co., Ltd. announced that New Element Pharmaceutical had signed an exclusive commercialization cooperation agreement with the subsidiary of Kangzhe Pharmaceutical Holdings Co., Ltd. for the Class 1 new drug ABP-671, indicated for the treatment of gout and hyperuricemia, in mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region.

On December 3, Therapeutics announced that it had signed an exclusive global licensing and collaboration agreement with Novartis regarding the Huntington's disease project PTC518 and its related molecules. Under the agreement, PTC will receive an upfront payment of $1 billion, as well as up to $1.9 billion in development, regulatory, and sales milestone payments.

Recently, UCB China and Zhejiang Bright Gene Biomedical Co., Ltd. signed a cooperation agreement for the commercial promotion of Bimekizumab (brand name: Beijiele®) in the Chinese market, fully leveraging their respective strengths to accelerate the launch process of Bimekizumab in China, and jointly bringing this innovative therapy to benefit more patients.

Technology-Driven Drug Research

On November 26, researchers Yichuan Xiao from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences, Mingyue Zheng from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Qingquan Luo, Chief Physician from the Department of Thoracic Surgery at Shanghai Chest Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and Zhiyu Ni, Professor from Hebei University of Engineering, published a research paper titled **Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity** in the Nature Aging, a sub-journal of Nature. The study found that aging significantly reduces the infiltration of CD8+ tissue-resident memory T (TRM) cells in the tumor microenvironment. This subset of cells is considered to have potent anti-tumor effects among CD8+ T cells, which may be a key mechanism underlying age-related dysfunction of CD8+ T cells.

[1]Pei, S., Deng, X., Yang, R. et al. Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity. Nat Aging (2024). https://doi.org/10.1038/s43587-024-00746-5

Live Broadcast Preview